Genentech announces Bill Anderson as new CEO
Genentech, the biotech subsidiary of Roche, has announced that Genentech veteran, Ian Clark, will retire as CEO on 1 January. Ian Clark performed his role as the CEO of Genentech for the last 15 years, bringing through 15 new drugs in the process and dealing with the after-effects of Roche’s buyout of the company.
Bill Anderson takes the positon of CEO after having worked within Genentech for the last decade. He has held a number of positions within the company and will switch to the role from his current position as North American commercial chief, a position he has held since July. Prior to this, he held the position of global product strategy chief for Roche and headed Genentech’s bio-oncology business.
"Bill is an outstanding leader with a deep understanding of the company and proven expertise in bringing important medicines to people with serious diseases," said Daniel O'Day, CEO of Roche's pharmaceuticals division.
- Genentech plans second Phase 3 Alzheimer's trial following endpoint failures
- Mylan’s pathway to launch of biosimilar to Herceptin cleared by Roche
- Genentech oncology head leaves for Bellicum CEO role
- Juno Therapeutics bring in new executive vice president
- Roche’s ground-breaking MS drug delayed by manufacturing issues